Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ETBX 011

Next Previous
Drug Profile

ETBX 011

Alternative Names: Ad5 [E1-, E2B-]-CEA; AD5 CEA vaccine; Ad5[E1-,E2b-]-CEA vaccine; Adenoviral CEA vaccine; CEA-targeted vaccine - ImmunityBio; ETBX-011

Latest Information Update: 26 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Etubics Corporation
  • Developer ImmunityBio; National Cancer Institute (USA)
  • Class Antineoplastics; Cancer vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Colorectal cancer; Pancreatic cancer; Solid tumours; Triple negative breast cancer
  • No development reported Liver cancer

Most Recent Events

  • 12 Dec 2024 NantKwest terminates the phase I/II QUILT-3.060 trial for Pancreatic cancer (Combination therapy, Second-line therapy or greater) in USA (NCT03329248)
  • 08 Aug 2024 NantCell terminates a phase I/II trial in Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (SC) (NCT03127098)
  • 01 Aug 2024 ImmunityBio terminates a QUILT-3.080 phase I/II trial in Pancreatic cancer (Combination therapy, Second-line therapy or greater) in USA (IV) prematurely (NCT03586869)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top